Therapeutic efficacy of liposomal Grb2 antisense oligodeoxynucleotide (L-Grb2) in preclinical models of ovarian and uterine cancer.
Oncotarget
OD Lara, E Bayraktar, P Amero, S Ma, C Ivan, W Hu, Y Wang, LS Mangala, P Dutta, P Bhattacharya, AT Ashizawa, G Lopez-Berestein, C Rodriguez-Aguayo, AK Sood
Evaluation of molecular subtypes and clonal selection during establishment of patient-derived tumor xenografts from gastric adenocarcinoma.
Communications Biology
AL Peille, V Vuaroqueaux, SS Wong, J Ting, K Klinger, B Zeitouni, M Landesfeind, WH Kim, HJ Lee, SH Kong, I Wulur, S Bray, P Bronsert, N Zanella, G Donoho, HK Yang, HH Fiebig, C Reinhard, A Aggarwal
Genetic mutation profile of Chinese HER2-positive breast cancers and genetic predictors of responses to Neoadjuvant anti-HER2 therapy.
Breast Cancer Research And Treatment
K Li, N Liao, B Chen, G Zhang, Y Wang, L Guo, G Wei, M Jia, L Wen, C Ren, L Cao, H Mok, C Li, J Lin, X Chen, Z Zhang, T Hou, M Li, J Liu, CM Balch, N Liao
Whole Exome Sequencing of Multi-Regional Biopsies from Metastatic Lesions to Evaluate Actionable Truncal Mutations Using a Single-Pass Percutaneous Technique.
Cancers
V Heong, D Tay, SE Goh, B Wee, TZ Tan, R Soo, B Pang, D Lim, A Gopinathan, S Ow, CE Chee, BC Goh, SC Lee, WP Yong, A Wong, MFM Omar, R Soong, DS Tan
Metabolic Fingerprinting Links Oncogenic PIK3CA with Enhanced Arachidonic Acid-Derived Eicosanoids.
Cell
N Koundouros, E Karali, A Tripp, A Valle, P Inglese, NJS Perry, DJ Magee, S Anjomani Virmouni, GA Elder, AL Tyson, ML Dória, A van Weverwijk, RF Soares, CM Isacke, JK Nicholson, RC Glen, Z Takats, G Poulogiannis
PI 3-kinase delta enhances axonal PIP3 to support axon regeneration in the adult CNS.
Embo Molecular Medicine
B Nieuwenhuis, AC Barber, RS Evans, CS Pearson, J Fuchs, AR MacQueen, S van Erp, B Haenzi, LA Hulshof, A Osborne, R Conceicao, TZ Khatib, SS Deshpande, J Cave, C Ffrench-Constant, PD Smith, K Okkenhaug, BJ Eickholt, KR Martin, JW Fawcett, R Eva
Blockade of VEGF-C signaling inhibits lymphatic malformations driven by oncogenic PIK3CA mutation.
Nature Communications
I Martinez-Corral, Y Zhang, M Petkova, H Ortsäter, S Sjöberg, SD Castillo, P Brouillard, L Libbrecht, D Saur, M Graupera, K Alitalo, L Boon, M Vikkula, T Mäkinen
DHA Affects Microtubule Dynamics Through Reduction of Phospho-TCTP Levels and Enhances the Antiproliferative Effect of T-DM1 in Trastuzumab-Resistant HER2-Positive Breast Cancer Cell Lines.
Cells
S D'Amico, EK Krasnowska, I Manni, G Toietta, S Baldari, G Piaggio, M Ranalli, A Gambacurta, C Vernieri, F Di Giacinto, F Bernassola, F de Braud, M Lucibello
Tumor Location Is Associated With the Prevalence of Braf And Pik3ca Mutations in Patients with Wild-Type Ras Colorectal Cancer: A Prospective Multi-Center Cohort Study in Japan.
Translational Oncology
H Taniguchi, K Uehara, G Nakayama, H Nakayama, T Aiba, N Hattori, M Kataoka, Y Nakano, Y Kawase, O Okochi, H Matsuoka, S Utsunomiya, E Sakamoto, Y Mori, S Umeda, T Shikano, K Komori, M Tajika, S Kadowaki, K Muro, Y Yatabe
Proteomic Characterization of Colorectal Cancer Cells versus Normal-Derived Colon Mucosa Cells: Approaching Identification of Novel Diagnostic Protein Biomarkers in Colorectal Cancer.
International Journal Of Molecular Sciences
M Ludvigsen, L Thorlacius-Ussing, H Vorum, MP Moyer, MT Stender, O Thorlacius-Ussing, B Honoré
Frequency and spectrum of PIK3CA somatic mutations in breast cancer.
Breast Cancer Research : Bcr
O Martínez-Sáez, N Chic, T Pascual, B Adamo, M Vidal, B González-Farré, E Sanfeliu, F Schettini, B Conte, F Brasó-Maristany, A Rodríguez, D Martínez, P Galván, AB Rodríguez, A Martinez, M Muñoz, A Prat
Multimodal Targeted Deep Sequencing of Circulating Tumor Cells and Matched Cell-Free DNA Provides a More Comprehensive Tool to Identify Therapeutic Targets in Metastatic Breast Cancer Patients.
Cancers
C Keup, M Storbeck, S Hauch, P Hahn, M Sprenger-Haussels, O Hoffmann, R Kimmig, S Kasimir-Bauer
Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial.
Experimental Hematology & Oncology
V Subbiah, EI Dumbrava, Y Jiang, KZ Thein, A Naing, DS Hong, S Fu, SA Piha-Paul, AM Tsimberidou, F Janku, F Meric-Bernstam, R Kurzrock, G Falchook
Safety and efficacy of sirolimus combined with endocrine therapy in patients with advanced hormone receptor-positive breast cancer and the exploration of biomarkers.
Breast (Edinburgh, Scotland)
Z Yi, B Liu, X Sun, G Rong, W Wang, H Li, X Guan, L Li, J Zhai, C Li, H Qian, F Ma, B Xu
Establishment and characterization of patient-derived xenografts as paraclinical models for head and neck cancer.
Bmc Cancer
HN Kang, JH Kim, AY Park, JW Choi, SM Lim, J Kim, EJ Shin, MH Hong, KH Pyo, MR Yun, DH Kim, H Lee, SO Yoon, DH Kim, YM Park, HK Byeon, I Jung, S Paik, YW Koh, BC Cho, HR Kim
Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications.
Breast Cancer Research : Bcr
C Vernieri, F Corti, F Nichetti, F Ligorio, S Manglaviti, E Zattarin, CG Rea, G Capri, GV Bianchi, F de Braud
The genetic architecture of breast papillary lesions as a predictor of progression to carcinoma.
Npj Breast Cancer
T Kader, K Elder, M Zethoven, T Semple, P Hill, DL Goode, N Thio, D Cheasley, SM Rowley, DJ Byrne, JM Pang, IM Miligy, AR Green, EA Rakha, SB Fox, GB Mann, IG Campbell, KL Gorringe